These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 858213)

  • 1. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L; Asbury M; Shelton J; Harrison I
    Clin Pharmacol Ther; 1977 May; 21(5):602-9. PubMed ID: 858213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spironolactone and potassium canrenoate in normal man.
    Ramsay L; Shelton J; Harrison I; Tidd M; Asbury M
    Clin Pharmacol Ther; 1976 Aug; 20(2):167-77. PubMed ID: 780038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects.
    Ramsay LE; Shelton JR; Tidd MJ
    Br J Clin Pharmacol; 1976 Jun; 3(3):475-82. PubMed ID: 788750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative potency of prorenoate and spironolactone in normal man.
    Ramsay L; Harrison I; Shelton J; Tidd M
    Clin Pharmacol Ther; 1975 Oct; 18(4):391-400. PubMed ID: 1100306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response relationships for spironolactone at steady state.
    McInnes GT; Perkins RM; Shelton JR; Harrison IR
    Clin Pharmacol Ther; 1982 Mar; 31(3):317-23. PubMed ID: 7060315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Canrenone--the principal active metabolite of spironolactone?
    Ramsay LE; Shelton JR; Wilkinson D; Tidd MJ
    Br J Clin Pharmacol; 1976 Aug; 3(4):607-12. PubMed ID: 22216502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
    Andriulli A; Arrigoni A; Gindro T; Karbowiak I; Buzzetti G; Armanini D
    Digestion; 1989; 44(3):155-62. PubMed ID: 2697627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG; Lundborg P; Persson BA; Regårdh CG
    Drug Metab Dispos; 1979; 7(2):103-7. PubMed ID: 38071
    [No Abstract]   [Full Text] [Related]  

  • 9. Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate.
    McInnes GT; Shelton JR; Harrison IR
    Clin Pharmacol Ther; 1981 May; 29(5):679-86. PubMed ID: 7214797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of spironolactone, canrenone and canrenoate-K on cytochrome P450, and 11beta- and 18-hydroxylation in bovine and human adrenal cortical mitochondria.
    Cheng SC; Suzuki K; Sadee W; Harding BW
    Endocrinology; 1976 Oct; 99(4):1097-106. PubMed ID: 976190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.
    Levine D; Ramsay L; Auty R; Branch R; Tidd M
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):381-6. PubMed ID: 786663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestogens with antimineralocorticoid activity.
    Losert W; Casals-Stenzel J; Buse M
    Arzneimittelforschung; 1985; 35(2):459-71. PubMed ID: 4039568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved method for comparative evaluation of aldosterone antagonists in healthy man.
    Casals-Stenzel J; Schmalbach J; Losert W
    Eur J Clin Pharmacol; 1977 Dec; 12(4):247-55. PubMed ID: 590311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of spironolactone, potassium canrenoate, and their common metabolite canrenone on Dimension Vista Digoxin Assay.
    Dasgupta A; Johnson MJ
    J Clin Lab Anal; 2010; 24(6):413-7. PubMed ID: 21089173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay.
    Armanini D; Karbowiak I; Goi A; Mantero F; Funder JW
    Clin Endocrinol (Oxf); 1985 Oct; 23(4):341-7. PubMed ID: 4064345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increase in the basal tone of guinea pig thoracic aorta induced by ouabain is inhibited by spironolactone canrenone and potassium canrenoate.
    Sorrentino R; Cirino G; Calignano A; Mancuso F; Sorrentino L; Andriuoli G; Pinto A
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):519-25. PubMed ID: 8891876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonism of fludrocortisone by spironolactone and canrenone.
    Huston GJ; Turner P
    Br J Clin Pharmacol; 1976 Feb; 3(1):201-4. PubMed ID: 973942
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparative effects of canrenoate-K and prorenoate-K upon aldosterone biosynthesis in perifused frog interrenal glands.
    Delarue C; Leboulenger F; Tonon MC; Jegou S; Leroux P; Kusmierek MC; Corvol P; Vaillant R; Vaudry H
    Steroids; 1979 Sep; 34(3):319-32. PubMed ID: 494369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of plasma and urinary canrenone for determination of bioavailability of spironolactone--comparison of tablets with solution/suspension.
    Tidd MJ; Ramsay LE; Shelton JR; Palmer RF
    Int J Clin Pharmacol Biopharm; 1977 May; 15(5):205-10. PubMed ID: 873663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spironolactone- and canrenone-induced changes in hepatic (Na+,K+)ATPase activity, surface membrane cholesterol and phospholipid, and fluorescence polarization in the rat.
    Miner PB; Sneller M; Crawford SS
    Hepatology; 1983; 3(4):481-8. PubMed ID: 6305816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.